
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

